ABSTRACT
The identification of TAA in melanomas has been paralleled by the demonstration of CTL-derived from solid tumors or ascites of patients with carcinomas, capable of recognizing autologous as well as HLA class I-matched allogeneic tumors.7' 11 One major challenge for treatment of carcinomas is the development of therapeutic tumor vaccinations targeting de fined T-cell epitopes. However, the knowledge about TAA in carcinomas is very limited in comparison to melanomas.
